Hexamethylene bisacetamide impairs NK cell-mediated clearance of acute T lymphoblastic leukemia cells and HIV-1-infected T cells that exit viral latency

The hexamethylene bisacetamide (HMBA) anticancer drug was dismissed due to limited efficacy in leukemic patients but it may re-enter into the clinics in HIV-1 eradication strategies because of its recently disclosed capacity to reactivate latent virus. Here, we investigated the impact of HMBA on the...

Descripción completa

Detalles Bibliográficos
Autores principales: Giuliani, Erica, Desimio, Maria Giovanna, Doria, Margherita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416400/
https://www.ncbi.nlm.nih.gov/pubmed/30867508
http://dx.doi.org/10.1038/s41598-019-40760-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416400/
https://www.ncbi.nlm.nih.gov/pubmed/30867508
http://dx.doi.org/10.1038/s41598-019-40760-x

Ejemplares similares